FASEB SRC on Melatonin Receptors: Actions and Therapeutics
FASEB SRC 关于褪黑激素受体:作用和治疗
基本信息
- 批准号:8200093
- 负责人:
- 金额:$ 1.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-06-10 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:AgonistAreaAttentionBiological ModelsCardiovascular DiseasesCardiovascular systemCellsCircadian Rhythm Sleep DisordersCircadian RhythmsClinical ResearchCollaborationsCommunitiesDataDevelopmentDisabled PersonsDiseaseEducationEuropeFosteringFranceFutureG-Protein-Coupled ReceptorsGoalsImmunityInflammationInflammatoryLeadLigandsMalignant NeoplasmsMarketingMelatoninMelatonin ReceptorsMental DepressionMetabolic DiseasesMethodsMinorityMolecularNeurodegenerative DisordersNorth AmericaObesityOrganPharmaceutical PreparationsPharmacologic SubstancePharmacologyPhysiologicalPhysiologyPreventionPublicationsReagentReceptor, Melatonin, MT1Receptor, Melatonin, MT2Recombinant melatoninResearchResearch Peer ReviewResearch PersonnelRoleScientistSenior ScientistSignal TransductionSleeplessnessStructureStudentsTechniquesTherapeuticTherapeutic AgentsTimeTissuesUnderrepresented MinorityWomanWorkagomelatineautism spectrum disorderbehavioral sensitizationbiomedical scientistcareer developmentdrug discoveryinterestnervous system disordernovel strategiesnovel therapeutic interventionnovel therapeuticsplanetary Atmospherepre-clinical researchpre-doctoralreceptorsymposiumtherapeutic targettool
项目摘要
DESCRIPTION (provided by applicant): The 2011 conference will focus on the role of melatonin receptors as potential therapeutic targets in depression, autism spectrum disorders, drug-induced behavioral sensitization, neurodegenerative diseases, insomnia, metabolic disorders, cardiovascular disorders, cancer, inflammatory disorders and altered immunity. Over the past 12 years, great advances have been achieved in the molecular and pharmacological actions of melatonin ligands. Furthermore, melatonin ligands acting on MT1 and MT2 receptors have been marketed for the treatment of insomnia, circadian disorders and depression (Rozerem, Takeda Pharmaceuticals North America, USA; Valdoxan, SERVIER, France, Europe). Other melatonin agonists for treatment of these disorders are currently in development. Our 2008 conference was highly successful at bringing together scientists from around the world working in the melatonin receptor area to present and discuss their new findings; we believe it is again time to bring melatonin receptor experts together to discuss the most recent advances since 2008 in this rapidly expanding field as well as to establish new directions for future research. The main emphasis of the conference will be on identifying and discussing novel therapeutic approaches for a variety of disease states (special emphasis on the CNS) using melatonin receptors as targets. The data presented and discussed will range from the identification of melatonin's physiological role to the structure and function of the receptor proteins and their role as therapeutic targets. This is the only conference that brings together investigators using melatonin receptors as targets for the development of therapeutic agents. Many new and diverse actions of melatonin with potential therapeutic benefits have been discovered since the 2008 conference that are of great interest to biomedical scientists and clinicians.
PUBLIC HEALTH RELEVANCE: This conference will bring together, for only the second time, a group of the world's foremost melatonin experts to present and discuss the physiology and pharmacology of melatonin receptors, the actions of melatonin, and new therapeutic melatonin ligands. In the foreseeable future, advances in therapeutic strategies using melatonin ligands will substantially increase as additional new melatonin ligands with efficacy at the level of melatonin receptors reach the market. This will have a significant and unique impact on the treatment and prevention of a wide range of diseases, including insomnia and other sleep disorders, circadian rhythm disturbances, neurological diseases, depression, cancer, immunological disorders, metabolic disorders and obesity, cardiovascular problems, inflammation, neurodegenerative disorders, and osteporosis.
描述(由申请人提供):2011年会议将重点关注褪黑激素受体在抑郁症、自闭症谱系障碍、药物诱导的行为敏化、神经退行性疾病、失眠、代谢紊乱、心血管疾病、癌症、炎症性疾病和免疫改变中作为潜在治疗靶点的作用。在过去的12年里,褪黑激素配体的分子和药理作用取得了很大的进展。此外,作用于MT 1和MT 2受体的褪黑激素配体已经上市用于治疗失眠、昼夜节律紊乱和抑郁症(Rozerem,Takeda Pharmaceuticals North America,USA; Valdoxan,SERVIER,France,Europe)。目前正在开发用于治疗这些病症的其他褪黑激素激动剂。我们2008年的会议非常成功地汇集了来自世界各地在褪黑激素受体领域工作的科学家,介绍和讨论他们的新发现;我们相信,现在是时候再次将褪黑激素受体专家聚集在一起,讨论自2008年以来在这个迅速扩大的领域的最新进展,并为未来的研究建立新的方向。会议的主要重点将是确定和讨论新的治疗方法,为各种疾病状态(特别强调中枢神经系统)使用褪黑激素受体作为目标。所提出和讨论的数据范围将从褪黑激素的生理作用的识别到受体蛋白的结构和功能及其作为治疗靶点的作用。这是唯一的会议,汇集了研究人员使用褪黑激素受体作为目标的治疗药物的发展。自2008年会议以来,已经发现了褪黑激素具有潜在治疗益处的许多新的和多样化的作用,这些作用引起了生物医学科学家和临床医生的极大兴趣。
公共卫生相关性:这次会议将第二次汇集一批世界上最重要的褪黑激素专家,介绍和讨论褪黑激素受体的生理学和药理学,褪黑激素的作用,以及新的治疗褪黑激素配体。在可预见的未来,使用褪黑激素配体的治疗策略的进展将随着在褪黑激素受体水平上具有功效的另外的新褪黑激素配体进入市场而显著增加。这将对治疗和预防广泛的疾病产生重大和独特的影响,包括失眠和其他睡眠障碍、昼夜节律紊乱、神经系统疾病、抑郁症、癌症、免疫紊乱、代谢紊乱和肥胖症、心血管问题、炎症、神经退行性疾病和骨质疏松症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID BLASK其他文献
DAVID BLASK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID BLASK', 18)}}的其他基金
Melatonin Supplementation in Complementary Breast Cancer Prevention
补充褪黑激素可辅助预防乳腺癌
- 批准号:
8115976 - 财政年份:2008
- 资助金额:
$ 1.5万 - 项目类别:
FASEB Summer Research Conference 2008 - Melatonin Receptors: Actions and Therapeu
2008 年 FASEB 夏季研究会议 - 褪黑素受体:行动与治疗
- 批准号:
7539763 - 财政年份:2008
- 资助金额:
$ 1.5万 - 项目类别:
Melatonin Supplementation in Complementary Breast Cancer Prevention
补充褪黑激素可辅助预防乳腺癌
- 批准号:
7470334 - 财政年份:2008
- 资助金额:
$ 1.5万 - 项目类别:
Melatonin Supplementation in Complementary Breast Cancer Prevention
补充褪黑激素可辅助预防乳腺癌
- 批准号:
7599182 - 财政年份:2008
- 资助金额:
$ 1.5万 - 项目类别:
LIGHT DURING DARKNESS AND BREAST CANCER PROGRESSION
黑暗和乳腺癌进展期间的光
- 批准号:
6383753 - 财政年份:2001
- 资助金额:
$ 1.5万 - 项目类别:
LIGHT DURING DARKNESS AND BREAST CANCER PROGRESSION
黑暗和乳腺癌进展期间的光
- 批准号:
6633641 - 财政年份:2001
- 资助金额:
$ 1.5万 - 项目类别:
LIGHT DURING DARKNESS AND BREAST CANCER PROGRESSION
黑暗和乳腺癌进展期间的光
- 批准号:
6514400 - 财政年份:2001
- 资助金额:
$ 1.5万 - 项目类别:
LIGHT DURING DARKNESS AND BREAST CANCER PROGRESSION
黑暗和乳腺癌进展期间的光
- 批准号:
6767631 - 财政年份:2001
- 资助金额:
$ 1.5万 - 项目类别:
相似国自然基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
- 批准号:2021JJ40433
- 批准年份:2021
- 资助金额:0.0 万元
- 项目类别:省市级项目
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
- 批准号:32001603
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
AREA国际经济模型的移植.改进和应用
- 批准号:18870435
- 批准年份:1988
- 资助金额:2.0 万元
- 项目类别:面上项目
相似海外基金
The attention area estimation and safety evaluation of BCI using SSVEP
基于SSVEP的BCI注意力区域估计和安全性评估
- 批准号:
26870684 - 财政年份:2014
- 资助金额:
$ 1.5万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Influence of attention and eye movement signals on population coding in area V4
注意和眼动信号对V4区群体编码的影响
- 批准号:
8189126 - 财政年份:2009
- 资助金额:
$ 1.5万 - 项目类别:
Influence of attention and eye movement signals on population coding in area V4
注意和眼动信号对V4区群体编码的影响
- 批准号:
8217067 - 财政年份:2009
- 资助金额:
$ 1.5万 - 项目类别:
Influence of attention and eye movement signals on population coding in area V4
注意和眼动信号对V4区群体编码的影响
- 批准号:
8423034 - 财政年份:2009
- 资助金额:
$ 1.5万 - 项目类别:
Influence of attention and eye movement signals on population coding in area V4
注意和眼动信号对V4区群体编码的影响
- 批准号:
7588129 - 财政年份:2009
- 资助金额:
$ 1.5万 - 项目类别:
Study on Land Use Control of Urbanization Control Area which paid attention to District where eased Development Permission System
关注放宽开发许可制度区的城镇化控制区土地利用控制研究
- 批准号:
19760423 - 财政年份:2007
- 资助金额:
$ 1.5万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Synthetic research about restructuring of the dialect, area word education that it paid attention to the communication consciousness, function
注重交际意识、功能的方言、方言教育重构综合研究
- 批准号:
15330183 - 财政年份:2003
- 资助金额:
$ 1.5万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Changing sea levels and (semi-)terrestrial landscape development in the Baltic Sea coastal area, with special attention to the role of the Darss Sill
波罗的海沿岸地区的海平面变化和(半)陆地景观发展,特别关注达斯海床的作用
- 批准号:
5385409 - 财政年份:2002
- 资助金额:
$ 1.5万 - 项目类别:
Research Units